KRC-01(KRC-01) - 在研适应症：局部晚期宫颈癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

局部晚期宫颈癌

非在研适应症-

原研机构

KORTUC, Inc.初创企业

在研机构

KORTUC, Inc.初创企业

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 KRC-01 相关的临床试验

NCT05570422 / Not yet recruiting临床1期

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 Intratumoral Injection Combined With Radiotherapy in Patients With Locally Advanced Cervical Cancer

This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled, multi-center study in 60 patients to evaluate the preliminary antitumor effect of KRC-01 in combination with CRT.

开始日期2025-04-01

申办/合作机构

KORTUC, Inc.初创企业

100 项与 KRC-01 相关的临床结果

登录后查看更多信息

100 项与 KRC-01 相关的转化医学

登录后查看更多信息

100 项与 KRC-01 相关的专利（医药）

登录后查看更多信息

1

项与 KRC-01 相关的文献（医药）

1988-04-01·Hybridoma

Mouse Monoclonal Antibodies with Restricted Specificity for Human Renal Cell Carcinoma and Ability to Modulate the Tumor Cell Growth In Vitro

Article

作者: Tokuyama, H ; Tokuyama, Y

Three mouse monoclonal antibodies (MAbs), KRC-1, -2 and -3(IgG1) were produced against cultured cells of human renal cell carcinoma (RCC) cell lines. All of them had restricted specificity for subset of RCC, but did not react with other tumor cell lines, tumor and normal tissues including kidney. The effect of these MAbs on the tumor cell growth in vitro was examined both in soft agar and in plate culture systems. All of them showed modulator effect on the tumor cell growth: KRC-1 showed stimulation effect and others, KRC-2 and -3, suppression one in the both systems. The specificity was observed in the modulator effects. KRC-1 detected a 135 kd glycoprotein in immunoblotting. KRC-2 detected a high molecular weight antigen (ca. 1200 kd) in gel filtration. All the antigens showed affinity for Con A lectin. Molecular properties of the antigens appeared to be different from those of previously reported RCC-associated antigens. The three MAbs seem to be useful to study mechanism of growth regulation in transformed cells.

100 项与 KRC-01 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期宫颈癌	临床1期	泰国	KORTUC, Inc.初创企业	2025-04-01
局部晚期宫颈癌	临床1期	印度	KORTUC, Inc.初创企业	2025-04-01
局部晚期宫颈癌	临床1期	英国	KORTUC, Inc.初创企业	2025-04-01